CIK 0001513525 · Non-accelerated filer<br>Smaller reporting company
Azora Therapeutics, Inc. (DE)
Sign in to watch- Ticker
- AZR
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 800667150
- Phone
- 434-422-9800
- Business address
- 16501 VENTURA BLVD, SUITE 400, ENCINO, CA, 91436
- Former names
- ADIAL PHARMACEUTICALS, INC., Adial Pharmaceuticals, L.L.C., ADial Pharmaceuticals, L.L.C.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 4 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-06-12 | Davidson Matt Chief Development Officer | Grant or award · Stock Option (Right to Buy) | +232,417 | 232,417 | ||
| 2026-06-12 | Young Wendy B. Director | Purchase · Pre-funded Warrant | +36,378 | $2.75 | $100K | 36,378 |
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | +61,647 | 61,647 | ||
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | +3,427 | 3,427 | ||
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | +1,822.13 | 1,822.13 | ||
| 2026-06-11 | Davidson Matt Chief Development Officer | Grant or award | +101.3 | 1,923.43 | ||
| 2026-04-07 | Anderson J. Kermit Director | Grant or award · Stock Option (Right to Buy) | +9,185 | 9,185 | ||
| 2026-04-07 | Goodman Tony Chief Operating Officer | Grant or award | +26,510 | 26,523 | ||
| 2026-04-07 | Shah Vinay Chief Financial Officer | Grant or award | +17,325 | 17,325 | ||
| 2026-04-07 | Schuyler Kevin Director | Grant or award | +9,185 | 9,213 | ||
| 2026-04-07 | Gilliland Robertson H. Director | Grant or award | +9,185 | 9,185 | ||
| 2026-04-07 | Claiborne Cary J Chief Executive Officer | Grant or award | +37,985 | 40,417 | ||
| 2025-05-29 | Gilliland Robertson H. Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2025-05-29 | Newman James W. Jr. Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2025-05-29 | Shah Vinay Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +9,000 | 9,000 | ||
| 2025-05-29 | Schuyler Kevin Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2025-05-29 | Claiborne Cary J Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +138,000 | 138,000 | ||
| 2025-05-29 | Goodman Tony Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +94,000 | 94,000 | ||
| 2025-05-29 | Anderson J. Kermit Director | Grant or award · Stock Option (Right to Buy) | +28,000 | 28,000 | ||
| 2024-12-05 | Claiborne Cary J Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +350,000 | 350,000 |
Page 2 of 10 · 190 trades